An Activist’s Guide to Shorter Treatment for Drug-Sensitive TB

Treatment Action Group (TAG) released the latest addition to its series of Activist Guides, An Activist’s Guide to Shorter Treatment for Drug-Sensitive Tuberculosis.

This new resource provides activists with information about two shorter treatment regimens for drug-sensitive TB: (1) a four-month regimen with high dose rifapentine given in place of rifampicin and moxifloxacin given in place of ethambutol for adults and adolescents (S31/A5349); and (2) a four-month regimen with standard doses of rifampicin, isoniazid, and pyrazinamide plus or minus ethambutol for children with non-severe TB (SHINE).

The guide is designed to provide activists with information about shorter treatment regimens for drug-sensitive TB, including recent trial results, key considerations for special populations, and anticipated access barriers. The guide also equips activists with actions they can take and arguments they can use to advocate for access to shorter treatment regimens for TB.

The guide, available for download here, is part of TAG’s signature series of Activist Guides. Other resources in this series include:

• An Activist’s Guide to Treatment for Drug-Resistant TB
• An Activist’s Guide to Rifapentine for the Treatment of TB Infection
• An Activist’s Guide to TB Diagnostic Tools
• An Activist’s Guide to the LAM Test Vital for Diagnosing TB in People Living with HIV/AIDS

For more TB news, check out the latest edition of the TB Online Weekly Newsletter.